间充质干细胞来源外泌体在移植物抗宿主病中的研究进展  

Research advance of mesenchymal stem cell-derived exosomes in graft-versus-host disease

作　　者：安慧慧 鱼玲玲 吴涛 An Huihui;Yu Lingling;Wu Tao(Department of Hematology,No.940 Hospital of Joint Logistics Support Force of Chinese People's Liberation Army,Lanzhou 730050,China)

机构地区：[1]中国人民解放军联勤保障部队第九四〇医院血液病内科,兰州730050

出　　处：《中华器官移植杂志》2023年第6期377-382,共6页Chinese Journal of Organ Transplantation

基　　金：甘肃省创新基地和人才计划(甘肃省白血病临床医学研究中心) (21JR7RA015)。

摘　　要：间充质干细胞(mesenchymal stem cell,MSC)是一种多能干细胞,具有自我更新分化、免疫活性和抗炎的潜力。异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT)是目前恶性血液病最有效的治疗方案,但移植后移植物抗宿主病(graft-versus-host disease,GVHD)的存在,阻碍了allo-HSCT的发展。目前已证实,间充质干细胞来源的外泌体(MSC-derived exosome,MSC-exo)在allo-HSCT和GVHD方面有广阔的治疗前景。本文现就MSC的免疫调节作用、MSC-exo的生物活性以及MSC-exo对于GVHD治疗及预防作用等的研究进展做一综述,旨在为未来GVHD的治疗提供新的思路。Mesenchymal stem cells(MSCs)are pluripotent stem cells with self-renewing differentiation,immunoactivity and anti-inflammatory potentials.Allogeneic hematopoietic stem cell transplantation(allo-HSCT)is currently the most effective treatment for hematologic malignancies.However,the presence of graft-versus-host disease(GVHD)after transplantation has hindered the development of allo-HSCT.MSC-derived exosomes(MSC-exo)derived from mesenchymal stem cells have been confirmed to have broad therapeutic prospects in allo-HSCT and GVHD.This review focused upon immunomodulatory effects of MSC,biological activities of MSC-exo and research advances of MSC-exo on managing GVHD,aiming to provide new therapeutic rationales for GVHD in the future.

关 键 词：间充质干细胞 外泌体 微RNA 异基因造血干细胞移植 移植物抗宿主病 

分 类 号：R457.7[医药卫生—治疗学]